This is a double blind, randomized, placebo controlled clinical trial to test the efficacy of the antioxidant formulation Fertilix® in lowering the levels of damaged sperm DNA in men diagnosed with moderate to high Sperm Oxidative DNA Damage (SODD)

Inclusion Criteria:

• Males with a sperm sample containing 8-OHdG levels > 15% and must be capable of producing an ejaculate containing >10million sperm upon study enrollment.
• Male is between 20-55 years of age seeking treatment for infertility with his partner at URA and who is a candidate for an IUI, IVF or IVF-ICSI (excluding donor egg) procedure.
• Female is between 20-42 years of age
• Female exhibits tubal patency on hydrosonogram or hysterosalpingogram (HSG)
• Female exhibits normal uterine cavity by hysteroscopy, hydrosonogram or hysterosalpingogram (HSG).

Exclusion Criteria

• Subjects with initial semen analysis of an ejaculate containing < 10 million sperm.
• Men who have been taking nutraceuticals, vitamins or other compounds known to have antioxidant activities within4 weeks of the study. No other supplements may be taken with Fertilix.
• Men who have hypersensitivity or an allergy to any of the ingredients in Fertilix®.
• Men who have been treated with a chemotherapeutic agent known to cause sterility, such as cyclophosphamide.
• Men who have taking anabolic steroids or testosterone replacement within 4 months of the study.
• Men currently being treated with a Ca++ channel blocker or other medical treatment known to adversely affect sperm production or function.
• Men with HIV, hepatitis B and C.